)
Lineage Cell Therapeutics (LCTX) investor relations material
Lineage Cell Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Acquired NeuroAirmid on November 12, adding worldwide rights to HUNT1, a Phase 1b/2a Huntington’s disease cell therapy; six participants had been dosed in REGEN4HD, with no serious adverse events reported.
Advanced OpRegen, OPC1, COR1, ReSonance and manufacturing-platform programs alongside the HUNT1 acquisition.
Financial highlights
Q3 2026 revenue was $1.434M versus $3.681M a year earlier, down 61%; lower Roche collaboration revenue and WDI services drove the decline.
Q3 operating expenses were $8.748M versus $7.467M; operating loss widened to $7.314M from $3.786M.
Q3 net income attributable to common shareholders was $4.232M versus a $29.781M loss; the result included a non-cash $11.944M warrant revaluation gain.
Nine-month revenue was $4.228M versus $7.948M; operating loss was $23.830M versus $30.071M, and net income was $0.902M versus a $64.384M loss.
Outlook and guidance
Cash, cash equivalents and marketable securities totaled $45.2M at September 30, 2026, and were expected to fund planned operations into Q2 2028.
Initial COR1 preclinical functional-model data were expected in Q1 2027; a ReSonance development-planning meeting with Denmark’s medicines agency was being prepared for Q4 2026.
HUNT1 clinical costs were estimated at less than $2M annually, with a CIRM award of up to $12M to UC Irvine and co-funding obligations of up to $3.1M.
Operating losses were expected to continue for several years, with additional capital needed as development and regulatory work advances.
- Scalable cell manufacturing underpins OpRegen, OPC1 and a seven-cell-type pipeline.LCTX
Corporate presentation - Pipeline expansion and clinical execution anchor the 2023 priorities.LCTX
Q4 2022 - Returned to profitability in Q2 2026 with strong clinical progress and cash runway into Q3 2028.LCTX
Q2 2026 - COR1 advances scalable, high-quality cell therapy for corneal disease with animal data expected soon.LCTX
Study update - OpRegen's cell therapy for dry AMD shows durable vision gains and global expansion with Roche.LCTX
H.C. Wainwright 4th Annual Ophthalmology Virtual Conference - Lead cell therapy programs in dry AMD and spinal cord injury show durable clinical benefits.LCTX
Corporate presentation - Q1 2026 revenue up 15% to $1.7M, $53.4M cash, pipeline and manufacturing milestones achieved.LCTX
Q1 2026 - Votes will be held on director elections, auditor ratification, and executive pay approval.LCTX
Proxy filing - Durable clinical gains, improved financials, and manufacturing strength drive program momentum.LCTX
Q4 2024
)
)
)
)
)
)
)
)